MedTrace Logo

Fimepinostat in Treating Brain Tumors in Children and Young Adults

NCT03893487 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-07-11

No results posted yet for this study

Summary

This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Recurrent Anaplastic Astrocytoma
  • Recurrent Glioblastoma
  • Recurrent Malignant Glioma
  • Recurrent Medulloblastoma

Interventions

DRUG

Fimepinostat

Fimepinostat capsules

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Sponsors & Collaborators

  • Pediatric Neuro-Oncology Consortium

    collaborator OTHER

  • Cannonball Kids' Cancer Foundation

    collaborator OTHER

  • Curis, Inc.

    collaborator INDUSTRY

  • Sabine Mueller, MD, PhD

    lead OTHER

Principal Investigators

  • Sabine Mueller, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-07
Primary Completion
2022-10-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03893487 on ClinicalTrials.gov